Infinity Reports IPI-145 Phase 1 Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced new data
from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145,
the company’s potent, oral inhibitor of phosphoinositide-3-kinase
1 Weinberg RA (2007) Cytoplasmic signaling circuitry programs many of the traits of cancer. In Jeffcock E, Zayatz E, and Mickey RK (Eds.) The biology of cancer (pp. 179-183). New York, NY: Garland Science, Taylor & Francis Group.